Raptor Pharmaceutical Corp. (Nasdaq: RPTP) announced top line results from a planned 18 month analysis of an ongoing 3 year Phase 2/3 clinical trial of RP103 (delayed-release cysteamine) for the potential treatment of Huntington’s disease (HD) in collaboration with the Centre Hospitalier Universitaire d’Angers (CHU d’Angers). A total of 96 patients with HD were randomized to treatment with RP103 or placebo. Eighty nine patients completed the initial 18 month phase. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) stock opened at $17.05 in last session, and closed at $17.14, while the day range of RPTP stock is $16.33-$17.72.The stock showed a positive weekly performance of 10.65%.
The Cell Therapeutics Inc (NASDAQ:CTIC) on Feb. 3 announced that Karen Ignagni has been appointed a director of CTIC, effective immediately. Ignagni currently serves as President and CEO of America’s Health Insurance Plans, or AHIP,which is the trade association representing U.S. health plans. Cell Therapeutics Inc (NASDAQ:CTIC) stock opened at $3.20, in last session and closed at $3.42, by gained 6.54%.The 52 week range was $0.97-$4.25.Company’s market capitalization is $499.96 million.
A biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company. Agenus Inc (NASDAQ:AGEN) stock gained 7.72% and finished the last session at $3.63.The EPS of the stock remained -1.23.Company’s market capitalization is $198.07 million.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, announced that Company management will present at the 2014 RBC Capital Markets’ Global Healthcare Conference on Tuesday, February 25, 2014 at 8:00 a.m. EST at the New York Palace Hotel in New York City. Pharmaceuticals Inc (NASDAQ:IDRA) stock opened the session at $4.80, and closed the session at $5.20.The 52 week range of the IDRA stock remained $0.19-$5.55 and the day range was $4.69-$5.20.